Crohn's Disease Treatment Market
Crohn's Disease Treatment Market Study by Anti-inflammatory Drugs, Immune System Suppressors, Antibiotics, Biologics, Anti-Diarrheal, and Pain Relievers from 2024 to 2034
Analysis of Crohn's Disease Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Crohn's Disease Treatment Market Outlook (2024 to 2034)
The global Crohn's disease treatment market is valued at US$ 4,474.8 million in 2024. The market size is projected to surge at a 2.8% CAGR, reaching a market valuation of US$ 5,912.5 million by 2034.
Crohn's disease is becoming more common throughout the world. The increase in diagnosed cases has boosted the need for effective treatments, driving market expansion. Ongoing research and development efforts have resulted in identifying new therapeutic targets and creating novel therapy alternatives. This has broadened the spectrum of Crohn's disease drugs and therapies accessible, giving patients and healthcare professionals greater options. Increased knowledge of Crohn's disease and improved diagnostic tools have resulted in earlier and more accurate diagnoses. As a result, more people are seeking medical treatment and obtaining prompt diagnoses, adding to the market's overall growth.
The smart use of technologies improves patient monitoring, allows for more seamless interaction among patients and healthcare professionals, and improves illness management. The increasing prevalence of biosimilars is a calculated adaptation to the growing need for cost-effective alternatives. As biosimilars achieve regulatory clearance and commercial acceptability, pharmaceutical companies that match their portfolios with these medicines benefit from a competitive edge.
The advent of gene editing tools, notably CRISPR-Cas9, heralds a paradigm shift in the market for Crohn's disease treatment. Companies that are researching precise genetic therapies are on the cutting edge of therapeutic innovation. This forward-thinking strategy, which targets the disease's molecular origins, entails a strategic bid for distinctiveness and market leadership.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 4,474.8 million |
| Forecasted Market Value (2034F) | US$ 5,912.5 million |
| Global Market Growth Rate (2024 to 2034) | 2.8% CAGR |
| Biologics Treatment Type Segment Growth Rate (2024 to 2034) | 3.0% |
| Hospital Pharmacies Segment Growth Rate (2024 to 2034) | 2.6% |
| North America Market Share (2024) | 71.3% |
| Latin America Market Share (2024) | 3.0% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors Are Boosting the Global Demand for Crohn's Disease Treatment?
"Increasing Adoption of Value-based Healthcare Models"
One tactical development influencing the global Crohn's disease treatment industry is the growing use of value-based healthcare models. Businesses that focus on cost-effectiveness and better patient outcomes while connecting their strategy with value-based care are likely to thrive in the changing healthcare industry. This strategy entails teamwork in showcasing the medicines' value proposition and creating payment schemes incentivizing favorable patient outcomes. Investors appreciate the firms' strategic vision in adopting value-based healthcare, as they anticipate stable income streams and market stability in the face of shifting payment models.
The market for Crohn's disease treatment now revolves around biologics, especially anti-TNF medications like infliximab and adalimumab. These intricate biological medicines successfully reduce the inflammation linked to the illness by focusing on particular immune system components. Their demonstrated effectiveness and the ongoing development of new biologics are what propel their market dominance.
The market has seen a notable increase in convenience and flexibility with the introduction of oral small-molecule treatments. Oral formulations offer a unique competitive advantage over injectable biologics by accommodating patient preferences and promoting compliance.
"Growing Investments in Microbiome Modulation"
Pharmaceutical firms are increasingly investing strategically in the study and manipulation of the gut microbiota, which drives the evolution of microbiome modulation as a therapeutic pathway. This new method presents chances for creative probiotic and prebiotic compositions and aligns with a comprehensive paradigm change. Leading companies in this trend position themselves to lead the market by leveraging new scientific discoveries and meeting the need for all-encompassing, evidence-based treatments in the field of Crohn's disease management. Investors anticipate the value creation associated with ground-breaking microbiome-based medicines and consider such strategic investments as signs of forward-thinking and possible market distinctiveness.
"Rising Emphasis on Patient-centric Approaches"
The Crohn's disease treatment market is strategically moving toward holistic illness management, as seen by the emphasis on patient-centric methods. Businesses prioritizing adherence solutions, assistance programs, and patient education remain modern with changing healthcare paradigms. This movement acknowledges the relationship between commercial success, therapeutic outcomes, and patient pleasure. Pharmaceutical companies can acquire a competitive edge and improve their corporate image by using patient-centric models. This can also encourage patient and healthcare provider loyalty. Companies that strategically connect with patient requirements will be well-positioned in the face of changing healthcare dynamics and rising demands for all-inclusive care solutions.
Which Factors Poses Challenges to this Market?
"Challenges in Early Diagnosis"
It is still difficult to diagnose Crohn's disease promptly, which affects patient outcomes and economic dynamics. To enable early detection, companies operating in this domain are required to allocate resources towards diagnostic innovations and awareness initiatives. Not only is it medically necessary to streamline diagnostic procedures, but it's also a calculated strategy to gain market share by enhancing illness management.
"Development of Resistance to Therapies"
Pharmaceutical businesses must constantly innovate to keep ahead of the changing dynamics of illness, as patients can grow resistant to particular medications. To overcome the inherent difficulty of therapeutic resistance in the Crohn's disease industry, commercial methods such as developing a pipeline of alternative therapies and investigating novel mechanisms of action are imperative.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
The North American Crohn's disease treatment market share is projected to witness significant expansion, with the Crohn's disease treatment market in the United States leading at a 2.7% CAGR through 2034. In the Latin America Crohn's disease treatment market, Brazil is anticipated to be at the forefront with a 4.0% CAGR through 2034.
Why is the Demand Surging in the United States?
"Increasing Patient Pool and Disease Awareness Boosts Growth in the United States"
| Country | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.7% |
The demand for Crohn's disease treatment in the United States is anticipated to surge at a 2.7% CAGR through 2034. The United States' patient pool is expanding due to rising awareness of Crohn's disease and advancements in diagnostic technology. Pharmaceutical firms now have a profitable chance to take a bigger chunk of this growing market by creating and promoting tailored medicines. One important path for market expansion is provided by biologic medications, which are an essential component in the treatment of Crohn's disease. Companies that research and market novel biologics can acquire a competitive edge, stand out in a crowded market, and get premium pricing since these products are the preferred option for many patients.
Product development and market entrance can be accelerated by utilizing accelerated regulatory procedures and designation programs, such as orphan drug status. Businesses can earn longer market exclusivity periods and a shorter time to market by carefully navigating regulatory frameworks to get priority review and market exclusivity.
Why is Brazil Emerging as a Lucrative Market?
"Increasing Healthcare Spending and Expanding Middle Class Nurture Growth in Brazil"
| Country | Value CAGR (2024 to 2034) |
|---|---|
| Brazil | 4.0% |
The market growth for Crohn's disease treatment in Brazil is estimated at a 4.0% CAGR through 2034. Brazil is witnessing a rise in healthcare expenditures due to the country's growing middle class and higher disposable incomes. Modern and efficient Crohn's disease treatments are in greater demand as people have more access to healthcare. Pharmaceutical businesses could gain from this development by matching this demographic's changing tastes with their product offers. Pharmaceutical businesses can benefit from Brazil's government initiatives and public health programs that strive to enhance healthcare results and accessibility. Enhancing market penetration and establishing a favorable market position can be achieved by aligning with national health goals and engaging in cooperative efforts with public health authorities.
Category-wise Insights
Why are Biologics the Leading Treatment Type in this Market?
"Higher Efficacy Rates Boost Demand for Biologics"
| Segment | Value Share (2024) |
|---|---|
| Biologics (Treatment Type) | 38.0% |
Based on treatment type, the biologics segment captured 38.0% of market shares in 2024. Comparing biologics to traditional therapies, biologics often exhibit greater success rates in remission induction and maintenance. This higher efficacy is especially important for treating moderate-to-severe instances of Crohn's disease, which is why patients and healthcare professionals choose biologics. Biologics are used in conjunction with the growing focus on early intervention in the treatment of Crohn's disease. Biologic therapy is becoming increasingly popular as it can lead to better results later on in the course of the disease, such as greater rates of remission and slower disease progression.
Why are Hospital Pharmacies the Top Distribution Channel?
"Access to Specialized Administration Surges Demand for Hospital Pharmacies"
| Segment | Value Share (2024) |
|---|---|
| Hospital Pharmacies (Distribution Channel) | 44.8% |
Based on the distribution channel, the hospital pharmacies segment occupied 44.8% of market shares in 2024. In many cases, complicated treatment plans for Crohn's disease include intravenous biologic therapy infusions. Hospital pharmacists are prepared to manage the complexities of delivering these therapies, guaranteeing accurate dosing, close observation, and patient security during infusions. Hospital pharmacies gain by having staff members with specific medical training, such as nurses and pharmacists, who can manage the intricacies of treating patients with Crohn's disease. This knowledge is essential to guaranteeing that biologics and other specialty drugs used in the treatment of the illness are administered correctly.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
The market's competitive environment is ever-changing, with fierce competition among pharmaceutical companies vying to develop and retain a dominant position. These firms compete on a variety of fronts, including product innovation, market penetration, and price methods. Key companies in this market invest heavily in research and development to create innovative therapeutic solutions, with an emphasis on biologics, which have emerged as the main therapy method. The widespread popularity of current biologics has fuelled a competitive rush to launch next-generation medicines with improved effectiveness and safety profiles, contributing to a steady flood of sophisticated therapeutic choices.
Recent Developments
- In November 2023, Mesenchymal Stem Cells (MSCs) were identified as a new therapy option for Crohn's disease treatment. Mesenchymal stem cells (MSCs) have been proven beneficial in treating fistulizing Crohn's disease in clinical trials, including a phase III research conducted in 2016. Adipose-derived MSCs have been shown to increase fistula closure rates dramatically.
- In February 2023, RINVOQ, the first oral advanced treatment for individuals with moderately to severely active Crohn's disease (CD), was authorized by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Crohn's Disease Treatment Market Segmentation
-
By Treatment Type:
- Anti-inflammatory Drugs
- Immune System Suppressors
- Antibiotics
- Biologics
- Anti-Diarrheal
- Pain Relievers
-
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- The Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2024 to 2034 5.3.1. Antibiotics 5.3.2. Amino Salicylates 5.3.3. Corticosteroids 5.3.4. Immunomodulatory 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Type, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Drug Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Drug Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Drug Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Drug Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Drug Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2023 15.1.2.1. By Drug Type 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2023 15.2.2.1. By Drug Type 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2023 15.3.2.1. By Drug Type 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2023 15.4.2.1. By Drug Type 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2023 15.5.2.1. By Drug Type 15.5.2.2. By Distribution Channel 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2023 15.6.2.1. By Drug Type 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2023 15.7.2.1. By Drug Type 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2023 15.8.2.1. By Drug Type 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2023 15.9.2.1. By Drug Type 15.9.2.2. By Distribution Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2023 15.10.2.1. By Drug Type 15.10.2.2. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2023 15.11.2.1. By Drug Type 15.11.2.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2023 15.12.2.1. By Drug Type 15.12.2.2. By Distribution Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2023 15.13.2.1. By Drug Type 15.13.2.2. By Distribution Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2023 15.14.2.1. By Drug Type 15.14.2.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2023 15.15.2.1. By Drug Type 15.15.2.2. By Distribution Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2023 15.16.2.1. By Drug Type 15.16.2.2. By Distribution Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2023 15.17.2.1. By Drug Type 15.17.2.2. By Distribution Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2023 15.18.2.1. By Drug Type 15.18.2.2. By Distribution Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2023 15.19.2.1. By Drug Type 15.19.2.2. By Distribution Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2023 15.20.2.1. By Drug Type 15.20.2.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2023 15.21.2.1. By Drug Type 15.21.2.2. By Distribution Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2023 15.22.2.1. By Drug Type 15.22.2.2. By Distribution Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2023 15.23.2.1. By Drug Type 15.23.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Abbvie Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Celgene Corporation 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Genetech 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Johnson & Johnson 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Pfizer Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Prometheus Laboratories Inc. (Nestle) 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Salix Pharmaceuticals Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Takeda Pharmaceutical Ltd 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Janssen Pharmaceuticals 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. AstraZeneca 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 8: Latin America Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 11: Western Europe Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 20: East Asia Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness by Drug Type, 2024 to 2034
Figure 14: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 15: Global Market Attractiveness by Region, 2024 to 2034
Figure 16: North America Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 22: North America Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 28: North America Market Attractiveness by Drug Type, 2024 to 2034
Figure 29: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 30: North America Market Attractiveness by Country, 2024 to 2034
Figure 31: Latin America Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 43: Latin America Market Attractiveness by Drug Type, 2024 to 2034
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 46: Western Europe Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 52: Western Europe Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 58: Western Europe Market Attractiveness by Drug Type, 2024 to 2034
Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 61: Eastern Europe Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 73: Eastern Europe Market Attractiveness by Drug Type, 2024 to 2034
Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 76: South Asia and Pacific Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 88: South Asia and Pacific Market Attractiveness by Drug Type, 2024 to 2034
Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 91: East Asia Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 97: East Asia Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 103: East Asia Market Attractiveness by Drug Type, 2024 to 2034
Figure 104: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 106: Middle East and Africa Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 118: Middle East and Africa Market Attractiveness by Drug Type, 2024 to 2034
Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How Big is the Crohn's Disease Treatment Market?
The Crohn's disease treatment market size is valued at US$ 4,478.8 million in 2024.
What is the Projected CAGR of the Crohn's Disease Treatment Market?
The Crohn's disease treatment market is likely to rise at a 2.8% CAGR through 2034.
How Big Will the Crohn's Disease Treatment Market Be by 2034?
The Crohn's disease treatment market is expected to be worth US$ 5,912.5 million by 2034.
Which is the Leading Treatment Type in the Crohn's Disease Treatment Market?
Biologics witness high demand in the industry.
Which Country is Rising at a Higher CAGR in the Crohn's Disease Treatment Market?
The market in Brazil is expected to rise at a 4.0% CAGR through 2034.
Crohn's Disease Treatment Market